Provexis (PXS) Share Price, News & Analysis

Company Overview

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in various foods, beverages, and dietary supplement formats. It offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and heart function. The company sells its products through distributors and online channels. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.

Key Stats

• Today's Range: 0.62 to 0.62
• 50-Day Range: 0.61 to 0.78
• 52-Week Range: 0.06 to 0.95
• Volume: N/A
• Average Volume: 1.06 million shs
• Market Capitalization: £14.49 million
• P/E Ratio: N/A
• Dividend Yield: 5.06%
• Price Target: N/A
• Consensus Rating: N/A

PXS Stock Analysis - Frequently Asked Questions

How have PXS shares performed this year?

Provexis' stock was trading at GBX 0.65 on January 1st, 2025. Since then, PXS stock has decreased by 5.0% and is now trading at GBX 0.62.

How were Provexis' earnings last quarter?

Provexis plc (LON:PXS) posted its earnings results on Wednesday, September, 30th. The company reported ($0.02) earnings per share (EPS) for the quarter. Provexis had a negative trailing twelve-month return on equity of 68.68% and a negative net margin of 73.10%.

How do I buy shares of Provexis?

Shares of PXS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Provexis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Provexis investors own include Reckitt Benckiser Group (RB), Taylor Wimpey (TW), Bionano Genomics (BNGO), Bristol Myers Squibb (BMY), Bumble (BMBL), BEST (BEST) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 9/30/2020
• Today: 10/09/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Transportation
• Current Symbol: LON:PXS
• CIK: N/A
• Web: www.provexis.org
• Phone: +44-1753-861777
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX 0
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£619.15 thousand
• Net Margins: -73.10%
• Pretax Margin: N/A
• Return on Equity: -68.68%
• Return on Assets: -56.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.62
• Quick Ratio: 6.21

Sales & Book Value

• Annual Sales: £1.20 million
• Price / Sales: 12.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: GBX 0.01 per share
• Price / Book: 71.99

Miscellaneous

• Outstanding Shares: 2,345,891,000
• Free Float: N/A
• Market Cap: £14.49 million
• Optionable: Not Optionable
• Beta: 1.21